{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:52:50Z","timestamp":1789876370529,"version":"4.0.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Post-coronavirus disease 2019 (post-COVID-19) condition, previously referred to as long COVID, includes a post-acute syndrome defined by the presence of non-specific symptoms occurring usually 3\u00a0months from the onset of the acute phase and lasting at least 2\u00a0months. Patients with chronic lymphocytic leukemia (CLL) represent a high-risk population for COVID-19. Moreover, the response to SARS-CoV-2 vaccination is often absent or inadequate. The introduction of monoclonal antibodies (mAbs) in the treatment landscape of COVID-19 allowed to reduce hospitalization and mortality in mild\u2013moderate SARS-CoV-2 infection, but limited data are available in hematological patients. We here report the effective use of casirivimab\/imdevimab (CI) in the treatment of two CLL patients with persistent infection and post-COVID-19 condition. Full genome sequencing of viral RNA from nasopharyngeal swabs was performed at the time of COVID-19 diagnosis and before the administration of CI. Both patients experienced persistent SARS-CoV-2 infection with no seroconversion for 8 and 7\u00a0months, respectively, associated with COVID symptoms. In both cases after the infusion of CI, we observed a rapid negativization of the nasal swabs, the resolution of post-COVID-19 condition, and the development of both the IgG against the trimeric spike protein and the receptor-binding domain (RBD) of the spike protein. The analysis of the viral genome in the period elapsed from the time of COVID-19 diagnosis and the administration of mAbs showed the development of new mutations, especially in the <jats:italic>S<\/jats:italic> gene. The genome variations observed during the time suggest a role of persistent SARS-CoV-2 infection as a possible source for the development of viral variants. The effects observed in these two patients appeared strongly related to passive immunity conferred by CI treatment permitting SARS-CoV-2 clearance and resolution of post-COVID-19 condition. On these grounds, passive anti-SARS-CoV-2 antibody treatment may represent as a possible therapeutic option in some patients with persistent SARS-CoV-2 infection.<\/jats:p>","DOI":"10.3389\/fonc.2022.945060","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T09:22:42Z","timestamp":1664529762000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab\/imdevimab"],"prefix":"10.3389","volume":"12","author":[{"given":"Laura","family":"Ballotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierlanfranco","family":"D\u2019Agaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Segat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Koncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Martinez-Orellana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Dattola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Orsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Marcello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeone","family":"Dal Monego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Licastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Misin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Sbis\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Maria","family":"De Sabbata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Luzzati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32656-8","article-title":"6-month consequences of COVID-19 in patients discharged from hospital: A cohort study","volume":"397","author":"Huang","year":"2021","journal-title":"Lancet"},{"key":"B2","unstructured":"A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0388-x","article-title":"Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European conference on infections in leukemia (ECIL)","volume":"33","author":"Maschmeyer","year":"2019","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00573-8","article-title":"Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study","volume":"22","author":"Pinato","year":"2021","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without azithromycin in mild-to-Moderate covid-19","volume":"383","author":"Cavalcanti","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with covid-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.12.20169359","article-title":"Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: Initial three-month experience","volume":"12","author":"Joyner","year":"2020","journal-title":"medRxiv [Preprint]."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus etesevimab in mild or moderate covid-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-243469","article-title":"Effective use of monoclonal antibodies for treatment of persistent COVID-19 infection in a patient on rituximab","volume":"14","author":"Rabascall","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3390\/v13071202","article-title":"Successful clearance of 300 day SARS-CoV-2 infection in a subject with b-cell depletion associated prolonged (B-DEAP) COVID by REGEN-COV anti-spike monoclonal antibody cocktail","volume":"13","author":"Drouin","year":"2021","journal-title":"Viruses"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.07.004","article-title":"Resolution of one-year persisting COVID-19 pneumonia and development of immune thrombocytopenia in a follicular lymphoma patient with preceding rituximab maintenance therapy: A follow-up report and literature review of cases with prolonged infections","volume":"21","author":"Yasuda","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.25.21262417","article-title":"Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies","volume":"12","author":"Lee","year":"2021","journal-title":"Cancer Discov"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent plasma therapy for b-cell-depleted patients with protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab217","article-title":"The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient-a case study","volume":"8","author":"Sepulcri","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1417720","article-title":"Dynamic changes of the normal b lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy","volume":"7","author":"Schliffke","year":"2018","journal-title":"Oncoimmunology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006215","article-title":"Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia","volume":"6","author":"Bagacean","year":"2022","journal-title":"Blood Adv"},{"key":"B22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41408-022-00608-6","article-title":"Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients","volume":"12","author":"Borgogna","year":"2022","journal-title":"Blood Cancer J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.698169","article-title":"Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms","volume":"12","author":"Proal","year":"2021","journal-title":"Front Microbiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0868-6","article-title":"SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes","volume":"26","author":"Sungnak","year":"2020","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03148-w","article-title":"Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia","volume":"590","author":"Grant","year":"2021","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"103355","DOI":"10.1016\/j.ebiom.2021.103355","article-title":"Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series","volume":"67","author":"Truong","year":"2021","journal-title":"EBioMedicine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.02.21264267","article-title":"Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with b cell depletion","volume":"5","author":"Nussenblatt","year":"2021","journal-title":"medRxiv [Preprint]."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.07.015","article-title":"Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with b-cell malignancies","volume":"32","author":"Pommeret","year":"2021","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.945060\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T09:22:48Z","timestamp":1664529768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.945060\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":28,"alternative-id":["10.3389\/fonc.2022.945060"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.945060","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"article-number":"945060"}}